SCHEMBL3245210

SCHEMBL3245210

CC(C)N1CCN(S(=O)(=O)O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
TRPV4 Q9HBA0 5/20 0.38
EPHX2 P34913 1/20 0.36
CHRNA7 P36544 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
HRH3 Q9Y5N1 3/20 0.35
KCNH2 Q12809 2/20 0.35
CYP2D6 P10635 2/20 0.35
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CXCR2 P25025 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19066410 0.80 LMNA (0.33) LMNAGAAPOLBNPSR1L3MBTL1
SCHEMBL1746338 0.79
SCHEMBL973439 0.79 POLB (0.40) GAAALDH1A1POLBL3MBTL1TSHR
SCHEMBL28361930 0.79 KDM4E (0.38) LMNAGAAKDM4EALDH1A1MAPT
SCHEMBL7906446 0.78 LMNA (0.48) LMNAGAATRPV4EPHX2CHRNA7
SCHEMBL6320475 0.78 LMNA (0.48) LMNAGAATRPV4KDM4EALDH1A1
SCHEMBL18391573 0.78 LMNA (0.48) LMNAGAATRPV4EPHX2CHRNA7
SCHEMBL26203636 0.76 LMNA (0.47) LMNAGAATRPV4EPHX2CHRNA7
SCHEMBL12205468 0.76 POLB (0.50) LMNAGAATRPV4KDM4EALDH1A1
SCHEMBL8659738 0.76 KDM4E (0.42) LMNAGAAKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233947-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2016-01-12 US disclosed
US-20140243329-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-08-28 US disclosed
US-8748478-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-06-10 US disclosed
EP-2379521-B1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-01-22 EP disclosed
US-20130237547-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2013-09-12 US disclosed
US-8436041-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2013-05-07 US disclosed
WO-2010080397-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-15 WO disclosed
US-20100160337-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237547-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 LMNA 4330/4885GAA 2702/4885TRPV4 12/4885
US-20100160337-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 LMNA 4330/4885GAA 2702/4885TRPV4 12/4885
US-20140243329-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 LMNA 4330/4885GAA 2702/4885TRPV4 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.